[HTML] nih.gov

[HTML][HTML] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

JA McCubrey, LS Steelman, WH Chappell… - Oncotarget, 2012 - ncbi.nlm.nih.gov
Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by
genetic alterations in upstream signaling molecules such as receptor tyrosine kinases …
被引用次数：366 相关文章

[引用][C] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

J Mccubrey, L Steelman, W Chappell, S Abrams… - ONCOTARGET, 2012 - iris.unipa.it
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in
therapy resistance and how to overcome resistance. IRIS IRIS Home Sfoglia Macrotipologie & …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance

JA McCubrey, LS Steelman, WH Chappell, SL Abrams… - 2012 - thescholarship.ecu.edu
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic
alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK) …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

JA McCubrey, LS Steelman, WH Chappell… - …, 2012 - pubmed.ncbi.nlm.nih.gov
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic
alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK) …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

JA Mccubrey, LS Steelman, WH Chappell… - …, 2012 - iris.uniroma1.it
Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by
genetic alterations in upstream signaling molecules such as receptor tyrosine kinases …
[HTML] oncotarget.com

[HTML][HTML] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

JA McCubrey, LS Steelman, WH Chappell, SL Abrams… - Oncotarget, 2012 - oncotarget.com
Abstract James A. McCubrey 1, Linda S. Steelman 1, William H. Chappell 1, Stephen L.
Abrams 1, Richard A. Franklin 1, Giuseppe Montalto 2, Melchiorre Cervello 3, Massimo Libra …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

J McCubrey, LS Steelman, WH Chappell… - 2012 - publications.goettingen-research …
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic
alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK) …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

JA McCubrey, LS Steelman, WH Chappell, SL Abrams… - Oncotarget, 2012 - europepmc.org
Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by
genetic alterations in upstream signaling molecules such as receptor tyrosine kinases …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

JA Mccubrey, LS Steelman, WH Chappell, SL Abrams… - ONCOTARGET, 2012 - cris.unibo.it
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic
alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK) …

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

J Mccubrey, L Steelman, W Chappell, S Abrams… - ONCOTARGET, 2012 - iris.unimore.it
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic
alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK) …